Gonadorelin Peptide: Studies in Gondotropin Release and Synthesis

Gonadorelin is a synthetic peptide possessing ten amino acids, and all are joined in a sequential form.⁽¹⁾ Structurally similar to the endogenous GnRH, Gonadorelin has 1-2 amino acid changes within the sequence.⁽²⁾ Identical to the naturally present GnRH hormones, Gonadorelin is a peptide with the potential to act as a GnRH agonist and regulate gonadotropin levels.

Gonadorelin peptide may stimulate the anterior pituitary gland and increase the synthesis and release of endogenous gonadotropins, FSH, and LH.⁽³⁾ This is primarily why they are classified as GnRH agonists, as they produce the same effect as GnRH.

That said, when in high concentrations, Gonadorelin peptide may also potentially downregulate the GnRH receptors located in the pituitary gland. This peptide hormone may bind to the receptors, stimulating the gonadotropins’ secretion. Over time, the receptors become less sensitive towards this peptide, causing downregulation of the receptors, thereby reversibly inhibiting the release of LH and FSH.

Gonadorelin Peptide Research

Research studies suggest that continued and sustained exposure to the Gonadorelin peptide for 10 years in test models has been suggested to reduce the risk of instances of breast cancer up to 50%, and when exposed for a longer period of 15 years, the risk may be reduced by 70%.⁽⁴⁾ Gonadorelin peptides may exhibit the potential to block the impact of mitogens estrogen and progesterone, reduce breast cell exposure to these mitogens, and thereby potentially act as a preventative agent against breast cancer cell proliferation and development.

Furthermore, certain clinical studies⁽⁵⁾ have suggested that gonadotropin-releasing hormone analogs, such as Gonadorelin, may have had a positive impact on research models of ovarian hyperandrogenemia, i.e., excessive androgen synthesis, a state at which there is a greater risk of breast cancer development. Per Secretio G et al.:

“The postmenopausal ovary is an important source of excessive androgen production, which originates from the ovarian interstitial cell hyperplasia frequently present in breast cancer patients. We propose to counter the source of androgen excess in women with ovarian stromal hyperplasia, thus reducing the substrate for estrogen formation without completely inhibiting estrogen synthesis. Available evidence indicates that gonadotropin-releasing hormone analogs can be safely used for breast cancer prevention in postmenopausal women.” ⁽⁵⁾

Gonadorelin peptides may also have preventative effects on the development of cancer cells in the prostate. GnRH analogs such as Gonadorelin peptide have the potential to inhibit the synthesis of Luteinizing hormones due to the decreased sensitivity of the GnRH receptors, which causes a decline in testosterone and dihydrotestosterone production. The development of prostate cancer cells is directly proportionate to these testosterone levels; therefore, this cancer may potentially be inhibited through GnRH analogs. These theories are still under scientific discovery and investigation.

Additional research hypotheses surround Gonadorelin and similar GnRH analogs have included:

• Gonadorelin peptide may exhibit potential in suppressing Spermatogenesis and Gonadotropins.
• Studies⁽⁵⁾have suggested that GnRH analogs such as Gonadorelin peptide may reduce sperm count, potentially azoospermia, in male research models. Upon exposure, the average sperm count appeared reduced by 93% in all models, also causing azoospermia in three cases out of a total seven. The complete absence of sperms in the ejaculate characterizes azoospermia.
• Research⁽⁶⁾ has suggested that Luteinizing hormone may exert an impact on the brain, mainly the hippocampus. Neurological degeneration may be mitigated through blocking the synthesis and secretion of luteinizing hormone (LH), and this can potentially be achieved by GnRH analogs such as Gonadorelin peptide.
• Gonadorelin peptide is a promising complement to the diagnostic tests for determining the functioning of the gonadal axis.
• Research indicates that the pituitary secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) by Gonadorelin peptide may not depend on the concentration of these hormones; instead, it may depend on the proper working of the hypothalamic and pituitary axis. The greater the severity of the improper functioning of the hypothalamic and pituitary axis, the higher the secretion of the gonadotropins.

 
NOTE: These products are intended for laboratory research use only. This peptide is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.

References:

1. National Center for Biotechnology Information. PubChem Compound Summary for CID 638793, Gonadorelin. https://pubchem.ncbi.nlm.nih.gov/compound/Gonadorelin.
2. Philip GA Thomas, Alain Fontbonne, Drugs and reproduction. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/gonadorelin-acetate
3. Lepor, Herbert. “Comparison of single-agent androgen suppression for advanced prostate cancer.” Reviews in urology vol. 7 Suppl 5, Suppl 5 (2005): S3-S12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1477619/
4. Secreto G, Sieri S, Agnoli C, Grioni S, Muti P, Zumoff B, Sant M, Meneghini E, Krogh V. A novel approach to breast cancer prevention: reducing excessive ovarian androgen production in elderly women. Breast Cancer Res Treat. 2016 Aug;158(3):553-61. https://pubmed.ncbi.nlm.nih.gov/27393623/
5.  Bhasin S, Yuan QX, Steiner BS, Swerdloff RS. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in men: effects of long term treatment with GnRH agonist infusion and androgen. J Clin Endocrinol Metab. 1987 Sep;65(3):568-74. https://pubmed.ncbi.nlm.nih.gov/3114307/
6. Rao CV. Involvement of Luteinizing Hormone in Alzheimer Disease Development in Elderly Women. Reprod Sci. 2017 Mar;24(3):355-368. https://pubmed.ncbi.nlm.nih.gov/27436369/
7. Gonadorelin. https://www.mayoclinic.org/drugs-supplements/gonadorelin-intravenous-route-injection-route/description/drg-20067426